Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized heparin in hospitalized COVID-19 pneumonia
NCT04723563Phase 4Completed
- Sponsor
- Frederick Health
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of heparin in COVID-19 pneumonia, sponsored by Frederick Health. Primary endpoint: Need for mechanical ventilation at 28 days. Started Feb 2021; status: completed.
02
Drugs
heparin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04723563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723563.